The clinical research organisation is the first to achieve new business process quality certification from the IAOCR.
Momentum Pharma, a clinical research organisation (CRO) headquartered in London and New Mexico, US, has become the first organisation to achieve the new business process quality certification (BPQC) standard from the International Accrediting Organisation for Clinical Research (IAOCR).
Based in the UK and the US, the IAOCR provides a comprehensive range of internationally recognised accreditations built specifically for the clinical research industry in collaboration with industry leaders.
The BPQC certification enables CROs to embed quality practices and demonstrate their commitment to operational excellence in the core business areas of governance, business strategy and workforce processes. The BPQC helps to align all service providers within the clinical research ecosystem through a common quality standard; providing an internationally recognised model that enables collaborative working and continuous improvement.
“Clinical research is one of the few highly regulated industries that had an absence of quality standards for businesses and workforce,” explains Jacqueline Johnson North, chief executive of IAOCR. The quality standard has been developed with support from a global advisory board of clinical research industry stakeholders.
“Momentum Pharma was keen to be the first to undertake the in-depth assessment for BPQC,” she continued adding that the certification was a testament to the team.
Momentum Pharma was awarded The Queen’s Award for Enterprise for its outstanding international trade in March 2023.
